Moreover, the inhibition of TAM recruitment by a CSF1 neutralizing antibody in mammary tumors leads to a better chemosensitivity to paclitaxel, reduced tumor progression and metastasis that was associated with an increased survival of CD8+ T-cells. Here, CD8A is linked to neoplasm.